Related Experiment Videos
Oral contraceptives reduce lamotrigine plasma levels
Anne Sabers1, Inger Ohman, Jakob Christensen
1Danish Epilepsy Hospital, University of Aarhus, Denmark. anns@glostruphosp.kbhamt.dk
Neurology
|August 27, 2003
Summary
Oral contraceptives (OC) significantly reduce lamotrigine (LTG) plasma levels by over 50% in women. Monitoring LTG levels is crucial when starting or stopping OC therapy to ensure treatment efficacy and safety.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Women's Health
Background:
- Lamotrigine (LTG) is an anticonvulsant medication used to treat epilepsy and bipolar disorder.
- Oral contraceptives (OCs) are widely used by women of reproductive age.
- Potential drug interactions between LTG and OCs require investigation.
Purpose of the Study:
- To investigate the effect of oral contraceptives (OCs) on the steady-state plasma concentrations of lamotrigine (LTG).
Main Methods:
- A comparative study was conducted on women taking LTG.
- Plasma concentrations of LTG were measured in two groups: those taking LTG with OCs and those taking LTG without OCs.
- Dose-adjusted LTG levels (dose/body weight/plasma concentration) were analyzed.
Main Results:
- Women on LTG and OCs had significantly lower mean LTG plasma concentrations (13 µmol/L) compared to those on LTG alone (28 µmol/L) (p < 0.0001).
- The LTG dose/body weight/plasma concentration ratio was substantially higher in women on OCs (2.1 L/kg/day) versus those without OCs (0.8 L/kg/day) (p < 0.0001).
- OC co-medication resulted in a >50% reduction in LTG plasma levels.
Conclusions:
- Oral contraceptives significantly decrease lamotrigine plasma levels.
- Healthcare providers should monitor LTG plasma concentrations closely when women initiate or discontinue OC therapy.
- Adjustments in LTG dosage may be necessary during concurrent use or cessation of OCs to maintain therapeutic efficacy.